Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nvidia Corp (NVDA) vs 10X Genomics Inc (TXG) Price & Performance

Nvidia CorpTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Nvidia Corp vs 10X Genomics Inc — how do they compare? Nvidia Corp trades at $206.59 (market cap $4.92T), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Nvidia Corp is far larger — about 897.8× 10X Genomics Inc's market cap, and Nvidia Corp pays a 0.49% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

NVDATXG
Market Cap
$4.92T$5.48B
Sector
TechnologyHealth
52-Week High
$235.75$45.80
52-Week Low
$165.17$11.34
Enterprise Value
$4.86T$5.02B
Dividend Yield
0.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nvidia Corp

Nvidia (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $1.87 exceeding the $1.76 forecast. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97%. The stock faces resistance near $210, while support holds at $201.

Outlook remains positive due to AI-driven growth and robust profitability, but risks include peak AI spending concerns and competitive pressures. Analysts project a $325.86 price target, with 75% recommending Buy. Investors should weigh high valuation multiples against sustained earnings momentum.

10X Genomics Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nvidia Corp

NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.

Read more on NVDA

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG